Seguir
Mariann Harangi
Mariann Harangi
University of Debrecen Faculty of Medicine
Dirección de correo verificada de belklinika.com
Título
Citado por
Citado por
Año
The impact of obesity on the cardiovascular system
I Csige, D Ujvárosy, Z Szabó, I Lőrincz, G Paragh, M Harangi, S Somodi
Journal of diabetes research 2018, 2018
5482018
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
AJ Vallejo-Vaz, CAT Stevens, ARM Lyons, KI Dharmayat, T Freiberger, ...
The Lancet 398 (10312), 1713-1725, 2021
1782021
Hypertension in thyroid disorders
E Berta, I Lengyel, S Halmi, M Zrínyi, A Erdei, M Harangi, D Páll, EV Nagy, ...
Frontiers in endocrinology 10, 482, 2019
1442019
Serum paraoxonase activity changes in uremic and kidney-transplanted patients
G Paragh, L Asztalos, I Seres, Z Balogh, L Löcsey, I Kárpáti, J Mátyus, ...
Nephron 83 (2), 126-131, 1999
1191999
Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage
M Harangi, I Seres, Z Varga, G Emri, Z Szilvássy, G Paragh, É Remenyik
European Journal of Clinical Pharmacology 60, 685-691, 2004
1112004
Association of chemerin with oxidative stress, inflammation and classical adipokines in non‐diabetic obese patients
P Fülöp, I Seres, H Lőrincz, M Harangi, S Somodi, G Paragh
Journal of cellular and molecular medicine 18 (7), 1313-1320, 2014
862014
Contribution of animal models to the understanding of the metabolic syndrome: a systematic overview
O Varga, M Harangi, IAS Olsson, AK Hansen
Obesity Reviews 11 (11), 792-807, 2010
822010
Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
Z Balogh, I Seres, M Harangi, P Kovacs, GY Kakuk, GY Paragh
Diabetes and Metabolism 27 (5; PART 1), 604-610, 2001
802001
The human paraoxonase‐1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters
HZ Mirdamadi, F Sztanek, Z Derdak, I Seres, M Harangi, G Paragh
British journal of clinical pharmacology 66 (3), 366-374, 2008
742008
Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels
P Koncsos, I Seres, M Harangi, I Illyés, L Józsa, F Gönczi, L Bajnok, ...
Pediatric research 67 (3), 309-313, 2010
702010
The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease
G Paragh, I Seres, M Harangi, Z Balogh, L Illyes, J Boda, Z Szilvássy, ...
Diabetes & metabolism 29 (6), 613-618, 2003
702003
Determination of DNA damage induced by oxidative stress in hyperlipidemic patients
M Harangi, É Remenyik, I Seres, Z Varga, E Katona, G Paragh
Mutation Research/Genetic Toxicology and Environmental Mutagenesis 513 (1-2 …, 2002
652002
High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus
K Gaál, T Tarr, H Lőrincz, V Borbás, I Seres, M Harangi, P Fülöp, ...
Lipids in health and disease 15, 1-8, 2016
602016
Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia
G Paragh, D Tör’’ocsik, I Seres, M Harangi, L Illyés, Z Balogh, P Kovacs
Current medical research and opinion 20 (8), 1321-1327, 2004
602004
Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease
F Sztanek, I Seres, M Harangi, L Lőcsey, J Padra, GJR Paragh, L Asztalos, ...
Nephrology Dialysis Transplantation 27 (7), 2866-2872, 2012
512012
Orlistat increases serum paraoxonase activity in obese patients
M Audikovszky, G Pados, I Seres, M Harangi, P Fülöp, E Katona, L Illyés, ...
Nutrition, metabolism and cardiovascular diseases 17 (4), 268-273, 2007
502007
Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity
M Harangi, HZ Mirdamadi, I Seres, F Sztanek, M Molnár, A Kassai, ...
Translational Research 153 (4), 190-198, 2009
492009
Alteration of PON1 activity in adult and childhood obesity and its relation to adipokine levels
I Seres, L Bajnok, M Harangi, F Sztanek, P Koncsos, G Paragh
Paraoxonases in Inflammation, Infection, and Toxicology, 129-142, 2010
482010
Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects
H Lőrincz, M Katkó, M Harangi, S Somodi, K Gaál, P Fülöp, G Paragh, ...
Clinical endocrinology 81 (3), 370-377, 2014
452014
The molecular and clinical rationale of extracorporeal photochemotherapy in autoimmune diseases, malignancies and transplantation
P Szodoray, G Papp, B Nakken, M Harangi, M Zeher
Autoimmunity Reviews 9 (6), 459-464, 2010
452010
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20